The results of the PrEPVacc HIV vaccine trial conducted in Eastern and Southern Africa, which ran between 2020 and 2024, show conclusively that neither of the two experimental vaccine regimens tested reduced HIV infections among the study population ..read more

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials ..read more

Randomized controlled trials, or RCTs, are believed to be the best way to study the safety and efficacy of new treatments in clinical research ..read more

A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States ..read more

Physician scientists from City of Hope, one of the largest cancer research and treatment organizations in the United States, found that people with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes ..read more

When Michael Pirovolakis received an individualized gene therapy in a single-patient clinical trial at The Hospital for Sick Children (SickKids) in March 2022, the course of his condition was dramatically altered ..read more

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM) – similar to polio. Scientists are striving to better understand AFM, which has emerged in the United States with spikes in cases every other year, primarily in the late-summer months over the last decade ..read more

Patients with treatment-refractory cancers who received eligibility and testing waivers to participate in a large basket/umbrella oncology trial had similar rates of clinical benefit and adverse events as patients who participated in the trial without waivers ..read more

The SELECT trial found that semaglutide significantly reduces cardiovascular events in individuals with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or changes in HbA1c levels ..read more

The BEDROC trial found that extended-release ketamine tablets (R-107) significantly improve depressive symptoms in treatment-resistant depression patients, with the 180 mg dose showing the most efficacy. The treatment was well-tolerated with minimal side effects ..read more